Welcome to the international HTA database

Showing [23369 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	NIHR Horizon Scanning Centre (NIHR HSC)	InterVapor® System for the treatment of severe emphysema
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Imatinib (Glivec®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Teduglutide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. NICE technology appraisal guidance 304
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. NICE interventional procedures guidance 487
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Management of the extravasation of antineoplastic agents]
2014	Blue Cross Blue Shield Association (BCBS)	Artificial pancreas device systems
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ivermectin 1% topical cream for papulopustular rosacea
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Eltrombopag (Revolade®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interferon-free regimens for chronic hepatitis C genotype 1
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. NICE technology appraisal guidance 305
2014	National Institute for Health and Care Excellence (NICE)	Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. NICE interventional procedures guidance 493
2014	NIHR Health Technology Assessment programme	Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds
2014	Blue Cross Blue Shield Association (BCBS)	Special report: screening asymptomatic women with dense breasts and normal mammograms for breast cancer
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Thymosin beta-4 for epidermolysis bullosa
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lipegfilgrastim (Lonquex®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Obesity interventions delivered in primary care for patients with diabetes: a review of clinical effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. NICE technology appraisal guidance 306
2014	National Institute for Health and Care Excellence (NICE)	Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. NICE interventional procedures guidance 482
2014	NIHR Health Technology Assessment programme	European network for Health Technology Assessment Joint Action (EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis
2014	NIHR Health Technology Assessment programme	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials
2014	NIHR Horizon Scanning Centre (NIHR HSC)	CelluTome™ epidermal harvesting system for autologous skin grafting
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interferon-free regimens for genotype 1 chronic hepatitis C: a review of the clinical evidence and cost-effectiveness
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A14-21 (Fingolimod)]
2014	National Institute for Health and Care Excellence (NICE)	Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. NICE technology appraisal guidance 307
2014	National Institute for Health and Care Excellence (NICE)	Insertion of a magnetic bead band for faecal incontinence. NICE interventional procedures guidance 483
2014	NIHR Health Technology Assessment programme	Maximising the value of combining qualitative research and randomised controlled trials in health research: the QUAlitative Research in Trials (QUART) study a mixed methods study
2014	NIHR Health Technology Assessment programme	Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial)
2014	HAYES, Inc.	Antimicrobial central venous catheters
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2014	National Institute for Health and Care Excellence (NICE)	Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. NICE interventional procedures guidance 484
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Dinutuximab (Unituxin) for high risk neuroblastoma – maintenance therapy
2014	Health Council of the Netherlands Gezondheidsraad (GR)	ADHD: medication and society
2014	HAYES, Inc.	Combined positron emission tomography-computed tomography (PET-CT) for evaluating esophageal cancer
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Azithromycin (Zedbac®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Patient-controlled analgesia for pediatric surgical or cancer patients: clinical effectiveness
2014	National Institute for Health and Care Excellence (NICE)	Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 310
2014	National Institute for Health and Care Excellence (NICE)	Faecal microbiota transplant for recurrent Clostridium difficile infection. NICE interventional procedures guidance 485
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Blinatumomab for relapsed or refractory Philadelphia-negative B-precursor acute lymphoblastic leukaemia
2014	Health Council of the Netherlands Gezondheidsraad (GR)	Participation by young people with mental health problems
2014	HAYES, Inc.	Combined positron emission tomography-computed tomography (PET-CT) for evaluating gastric and colorectal cancers
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Aripiprazole monohydrate (Abilify Maintena®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal protective equipment for antibiotic resistant organisms in rehabilitation facilities: clinical evidence and guidelines
2014	NIHR Health Technology Assessment programme	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [ID726]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. NICE technology appraisal guidance 311
2014	National Institute for Health and Care Excellence (NICE)	Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. NICE interventional procedures guidance 478
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Lapatinib (Tyverb) for early HER2-positive breast cancer, neoadjuvant therapy in combination with trastuzumab
2014	NIHR Health Technology Assessment programme	Changing eating behaviours to treat childhood obesity in the community using Mandolean: the Community Mandolean randomised controlled trial (ComMando) - a pilot study
2014	HAYES, Inc.	Cranial orthotic devices for the treatment of positional cranial deformity
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Dolutegravir (Tivicay®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for tinnitus: clinical evidence and guidelines
2014	NIHR Health Technology Assessment programme	Aflibercept solution for injection for treating diabetic macular oedema [ID717]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sucroferric oxyhydroxide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 312
2014	National Institute for Health and Care Excellence (NICE)	Optical coherence tomography to guide percutaneous coronary intervention. NICE interventional procedures guidance 481
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Lutetium-177 for inoperable gastroenteropancreatic neuroendocrine tumours
2014	HAYES, Inc.	Intravenous iron for the treatment of iron deficiency with or without anemia in patients with chronic heart failure
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Paclitaxel albumin-bound nanoparticles (Abraxane®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines
2014	NIHR Health Technology Assessment programme	Dexamethasone intravitreal implant for treating diabetic macular oedema [ID653]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. NICE technology appraisal guidance 314
2014	National Institute for Health and Care Excellence (NICE)	Endoscopic thoracic sympathectomy for primary facial blushing. NICE interventional procedures guidance 480
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole
2014	HAYES, Inc.	Ligament Augmentation and Reconstruction System (LARS) for ligament repairs of the knee
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Certolizumab pegol (Cimzia®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Automated notification and reminder call systems: guidelines
2014	NIHR Health Technology Assessment programme	Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Canagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 315
2014	National Institute for Health and Care Excellence (NICE)	Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE interventional procedures guidance 475
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Rigosertib for higher risk myelodysplastic syndromes – second and subsequent line
2014	HAYES, Inc.	Preoperative physical therapy for severe osteoarthritis of the hip
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Bortezomib (Velcade®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Administration of naloxone in a home or community setting: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sipuleucel-T - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014	National Institute for Health and Care Excellence (NICE)	Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 316
2014	National Institute for Health and Care Excellence (NICE)	Transcranial magnetic stimulation for treating and preventing migraine. NICE interventional procedures guidance 477
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Sunitinib malate (Sutent) for renal cell carcinoma – adjuvant therapy
2014	HAYES, Inc.	Reverse shoulder total joint prosthesis
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Certolizumab pegol (Cimzia®) [in combination with methotrexate]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Continuous positive airway pressure for acute respiratory failure in the pre-hospital setting: guidelines
2014	National Institute for Health and Care Excellence (NICE)	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes. NICE technology appraisal guidance 317
2014	National Institute for Health and Care Excellence (NICE)	Arthroscopic trochleoplasty for patellar instability. NICE interventional procedures guidance 474
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Minicare H-2000 remote monitoring system for patients undergoing chemotherapy
2014	HAYES, Inc.	Revisional surgery for treatment of complications after bariatric surgery
2014	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Alogliptin (Vipidia®)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term 5HT3 antagonist use for alcohol dependence: clinical evidence and guidelines
2014	Malaysian Health Technology Assessment (MaHTAS)	Rapid blood test device for HIV, HBV, HCV, & syphillis
2014	National Institute for Health and Care Excellence (NICE)	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 319
2014	National Institute for Health and Care Excellence (NICE)	Radiofrequency ablation of the soft palate for snoring. NICE interventional procedures guidance 476
2014	NIHR Health Technology Assessment programme	The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for acute severe asthma